Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Versions (2) ▾
  1. 3/29/21
  2. 3/29/21
Copyright Holder:
Uploaded on:

March 29, 2021

No DOI assigned. To request one please log in.
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758

Infection Summary; Concomitant Medications and Transfusions; Adverse Experiences

Infection Summary
Has the patient had a presumed or confirmed invasive infection (e.g., sepsis, pneumonia, etc.) requiring oral or intravenous anti-infectives during study participation?
Type of Infection
Method of confirmation
Was a culture obtained?
Infection Summary - Culture information
Source Code
Culture Result
If positive result, indicate organism code
Infection Summary - Anti-infective
Was an anti-infective administered?
Infection Summary - Anti-infective
Empiric or therapeutic?
Anti-infective therapy ongoing?
Concomitant Medications and Transfusions
Medication Continuing?
Adverse Experiences
No Adverse Experience
Adverse Experiences
Adverse Experience Ongoing
Therapeutic Measures - Drug
Other therapeutic measures
Adverse Experience Outcome
Adverse Experience Relationship to Drug
Adverse Experiences - Investigator Signature

Similar models